Ignite Creation Date:
2025-12-24 @ 3:07 PM
Ignite Modification Date:
2026-01-05 @ 8:54 AM
Study NCT ID:
NCT03249792
Status:
TERMINATED
Last Update Posted:
2025-07-24
First Post:
2017-08-09
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-09-20
Start Date Type:
ACTUAL
Primary Completion Date:
2023-02-22
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-02-22
Completion Date Type:
ACTUAL
First Submit Date:
2017-08-09
First Submit QC Date:
None
Study First Post Date:
2017-08-15
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2024-02-05
Results First Submit QC Date:
None
Results First Post Date:
2024-07-24
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-08
Last Update Post Date:
2025-07-24
Last Update Post Date Type:
ACTUAL